Acetylcysteine | Clarification of the physician's order/request for information | No NOM |
Acetylcystein | Omission of a drug from the physician's order (indication not treated) | Untreated health problem |
Acetylcysteine | Clarification of the physician's order/request for information | Non-quantitative ineffectiveness |
Acyclovir | Dose error 1.5–10 times higher than normal (if drug had a normal therapeutic range) | Quantitative safety problem |
Albumin | Pharmaceutical form inappropriate or not available | Quantitative ineffectiveness |
Azithromycin | Clarification of the physician's order/request for information | Quantitative safety problem |
Calcium (oral) | Pharmaceutical form inappropriate or not available | No NOM |
Clonidine | Inappropriate dosage interval | Quantitative safety problem |
Clopidogrel | Clarification of the physician's order/request for information | No NOM |
Dexamethasone | Incomplete information in the physician's order | Quantitative safety problem |
Dopamine | Dose error 10 times higher than normal (if drug had a narrow therapeutic range) | Quantitative safety problem |
Esomeprazol | Inappropriate dosage interval | Quantitative safety problem |
Ethomidate | Dose error 4–10 times higher than normal (if drug had a narrow therapeutic range) | Quantitative safety problem |
Furosemide | Inappropriate dosage interval | Quantitative safety problem |
Hydrocortisone | Clarification of the physician's order/request for information | Quantitative safety problem |
Latex | Documented drug allergy | No NOM |
Levosimendan | Clarification of the physician's order/request for information | Non-quantitative ineffectiveness |
Magnesium | Dose error resulting in potentially toxic concentrations | Quantitative safety problem |
Nifedipine | Therapeutic duplication | Unnecessary medicine |
Nitazoxanide | Omission of a drug from the physician's order (indication not treated) | Non-quantitative ineffectiveness |
Octreotide | Information on the administration of parenteral/oral drugs | Non-quantitative ineffectiveness |
Octreotide | Information on the administration of parenteral/oral drugs | Non-quantitative safety problem |
Omeprazole | Inappropriate dosage interval | Quantitative safety problem |
Omeprazole | Inappropriate dosage interval | Quantitative safety problem |
Omeprazole | Inappropriate dosage interval | Quantitative safety problem |
Omeprazole | Interaction: clinically significant, requiring follow-up | No NOM |
Oseltamivir | Dose error very low in non-potentially life-saving drugs | Quantitative ineffectiveness |
Oseltamivir | Dose error very low in non-potentially life-saving drugs | Quantitative ineffectiveness |
Palivizumab | Omission of a drug from the physician's order (indication not treated | Untreated health problem |
Propranolol | Dose error 10 times higher than normal (if drug had a normal therapeutic range) | Quantitative safety problem |
Propofol | Adverse reaction related to precautions or contraindications | Quantitative safety problem |
Propofol | Adverse reaction related to precautions or contraindications | Quantitative safety problem |
Propofol | Adverse reaction with a threat to the life of the patient | Quantitative safety problem |
Quinine | Omission of a preventive measure to avoid adverse reactions | Non-quantitative safety problem |
Salbutamol | Route of administration that could lead to severe toxicity | Non-quantitative safety problem |
Salbutamol | Route of administration that could lead to severe toxicity | Quantitative safety problem |
Socium chloride | Route of administration that could lead to mild toxicity | Non-quantitative safety problem |
Sodium bicarbonate | Dose error resulting in potentially toxic concentrations | Quantitative safety problem |
Suxamethonium | Dose error resulting in potentially toxic concentrations | Quantitative safety problem |
Valproic acid | Interaction clinically significant, requiring follow-up | Quantitative ineffectiveness |
NOM, negative outcomes associated with medication.